Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma

European Journal of Cancer

Volumn 44, Issue 17, 2008, Pages 2634-2639

  Perfumo, C ^a   Parodi, S ^b   Mazzocco, K ^a   Defferrari, R ^a   Inga, A ^a   Haupt, R ^b   Fronza, G ^a   Tonini, G P ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

MDM2; Neuroblastoma; Polymorphism; Progression; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEFEROXAMINE; DOXORUBICIN; ETOPOSIDE; GUANINE; IFOSFAMIDE; ISOTRETINOIN; MDM2 SNP309 PROTEIN; MESSENGER RNA; PROTEIN MDM2; PROTEIN P53; REGULATOR PROTEIN; THIOTEPA; THYMINE; UNCLASSIFIED DRUG; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; DEMOGRAPHY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC TRAIT; GENOTYPE; HETEROZYGOTE; HUMAN; INFANT; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NUCLEIC ACID BASE SUBSTITUTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL;

CHILD; CHROMOSOMES, HUMAN, PAIR 2; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; MALE; NEUROBLASTOMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 55249091809     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.08.018     Document Type: Article

References (23)

1. Izbicki T., Mazur J., and Izbicka E. Epidemiology and etiology of neuroblastoma: an overview. Anticancer Res 23 1B (2003) 755-760
2. Escobar M.A., Grosfeld J.L., Powell R.L., et al. Long-term outcomes in patients with stage IV neuroblastoma. J Pediatr Surg 41 2 (2006) 377-381
3. Petitjean A., Achatz M.I., Borresen-Dale A.L., Hainaut P., and Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26 15 (2007) 2157-2165
4. Tweddle D.A., Pearson A.D., Haber M., et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 197 1-2 (2003) 93-98
5. Rodriguez-Lopez A.M., Xenaki D., Eden T.O., Hickman J.A., and Chresta C.M. MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells. Mol Pharmacol 59 1 (2001) 135-143
6. Slack A.D., Chen Z., Ludwig A.D., Hicks J., and Shohet J.M. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells. Cancer Res 67 6 (2007) 2448-2455
7. Bond G.L., Hu W., Bond E.E., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 5 (2004) 591-602
8. Bougeard G., Baert-Desurmont S., Tournier I., et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43 6 (2006) 531-533
9. Ruijs M.W., Schmidt M.K., Nevanlinna H., et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 15 1 (2007) 110-114
10. Hu Z., Jin G., Wang L., Chen F., Wang X., and Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: Evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 16 12 (2007) 2717-2723
11. Magnani C., Capocaccia R., Giordano L., et al. Expected number of childhood cancers in Italy, by region. Riv Ital Pediatr 18 (1992) 203-207
12. Ambros P.F., and Ambros I.M. Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37 6 (2001) 492-504
13. Ambros I.M., Benard J., Boavida M., et al. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21 11 (2003) 2077-2084
14. De Bernardi B., Nicolas B., Boni L., et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 21 8 (2003) 1592-1601
15. Hosmer D.W., and Lemeshow S. Applied logistic regression. second ed. (2000), John Wiley & Sons, New York
16. Marubini E., and Valsecchi M.G. Analysing survival data from clinical trials and observational studies (1995), John Wiley & Sons, New York
17. Goldman S.C., Chen C.Y., Lansing T.J., Gilmer T.M., and Kastan M.B. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am J Pathol 148 5 (1996) 1381-1385
18. McKenzie P.P., Guichard S.M., Middlemas D.S., Ashmun R.A., Danks M.K., and Harris L.C. Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. Clin Cancer Res 5 12 (1999) 4199-4207
19. Isaacs J.S., Saito S., and Neckers L.M. Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma. J Biol Chem 276 21 (2001) 18497-18506
20. Keshelava N., Zuo J.J., Chen P., et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 61 16 (2001) 6185-6193
21. Carr J., Bell E., Pearson A.D., et al. Increased frequency of aberrations in the p53/MDM2/p14 (ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res 66 4 (2006) 2138-2145
22. Van Maerken T., Speleman F., Vermeulen J., et al. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 66 19 (2006) 9646-9655
23. Barbieri E., Mehta P., Chen Z., et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 5 9 (2006) 2358-2365